Member Info for violindog

Would there be any benefit to Scancell and shareholders moving from Aim to the Main market? Or is it irrelevant with Redmile and Vulps holding such a large stake ?

Or perhaps bypass the Uk totally and head to the

Nasdaq? Guess it depends on the trial results. Certainly, USA funding ( if required) may be easier to raise if needed ?? Would love to know Scancell’s thinking !!

72 trades... very interesting , I hadn't figured it's all you can get for £10 . Very odd for such a small amount considering dealing charges.

Hi Cleanerworld, unfortunately E lily were purely focused on obesity and probably making sure that it will be their obesity drug that gets the government contract in return. ...brown envelopes etc..

David A Ricks, Chair and CEO of Eli Lilly and Company said:

We welcome this opportunity to partner with the UK government on tackling and preventing disease, and accelerating innovation to advance care delivery models. Today’s announcement is an important milestone, and we are pleased to reinforce Lilly’s commitment to improving health for people living with obesity and its serious consequences.Obesity is the second biggest preventable cause of cancer and a major contributor to ill health that prevents people from participating fully in work. This collaboration will bring together treatments and technologies developed by the life sciences sector and the health system seeking to demonstrate improved long-term health outcomes for those living with obesity.

The collaboration with Lilly aims to set the stage for government to work with industry to trial innovative approaches to treating obesity as part of a rounded package of care.

Buddha, as everyone knows ...my target is 50p.... but every day we are still getting those " 72 " trades so perhaps I'll reassess and aim for 72 😉

EE, I totally agree with your comments and the translation to Scancell re timeframes. Also, we don't have the same financial clout ...I wonder how much Moderna " pay" for each patient recruited at each trial site compared to what is offered by Scancell. Also, the likes of Moderna also have the political backing of the Government past and present.

I think I am answering my own question...Bobbust.. do you mean pauses built into the trial protocol ?

Bob, where do you get the info about the two hold points for safety ? Thanks

Scinv... believe me...the NHS is not known for its speed. Scancell have done very well recruiting and they can only work with the patients that they are presented with across multiple sites.

Hi Maivoce and others....well everything posted makes sense ..time will tell 🤞

EE.... its certainly not a desired outcome.

I just find it increasingly difficult to understand why Scancell, with all the incredible data published so far, has failed to attract a deal when we are so well positioned in the hot area of immunotherapy . Scancell have early data from both the Scib and Moditope trials presented at conferences ....the data is amazing.... yet other pharma companies in the same field ...with only pre clinical data... seam to land mega deals as Marcus keeps posting on the other board. If other companies get snapped up so early in their development are their products so superior ??

The only hope on the horizon is the mystery mAb being reviewed... so hopefully a mega deal for this and not another 5m giveaway.

It's a shame Merck didn't think Scancell had the potential but they have signed with Exelixis for head and neck and renal. Perhaps they may be interested in Scib / skin cancer.... but looking like we are the wall flower once again 😢

Exelixis (NASDAQ:EXEL) and Merck (NYSE:MRK) entered development collaboration to evaluate the combination of zanzalintinib with Merck’s anti-PD-1 therapy KEYTRUDA for the treatment of patients with head and neck squamous cell carcinoma.

The collaboration is also to evaluate the combination of and zanzalintinib with WELIREG in a phase 1/2 trial and two phase 3 pivotal trials for the treatment of patients with renal cell carcinoma.

Under the terms of the collaboration, Merck will supply KEYTRUDA for the ongoing, phase 3 STELLAR-305 pivotal trial in previously untreated PD-L1 positive recurrent or metastatic HNSCC.

In addition, Merck will sponsor a phase 1/2 trial and two phase 3 pivotal trials in RCC.

Merck will fund one of these phase 3 studies, and Exelixis will co-fund the phase 1/2 trial and the other phase 3 study, as well as supply zanzalintinib and cabozantinib.

Exelixis maintains all global commercial and marketing rights to zanzalintinib.

Looking like Merck has gone elsewhere ...

https://seekingalpha.com/news/4158193-exelixis-merck-sign-development-collaboration-for-head-neck-cancer-treatment-and-renal-cell-carcinoma

Matt, excellent point re the USA....

It would be marvellous if we have a pre signed deal ...dependant upon the trial results. Scancell have certainly placed enough data on the table following the initial results... had someone taken the bait ??

Matt, I agree completely. I would go far as to say that I hope Scancell have engaged an external professional media company to guide Scancell.

Yes, it makes not one jot of difference regarding a major offering a deal.... they will be privy to the small details... but it would certainly raise Scancell into the public eye on both sides of the Atlantic and with luck Australian media, on a continent where skin cancer is certainly on the rise.

Hooks, welcome!

Hi Moonparty, perhaps 72 will be the new 50 😃

14:04 hrs .... and our friend 72 pops up again !

Hi Moon and Matt....guess with the large 12% spread - bid @ 12.5 and offer @14p - they can move around the share price within this range and the resultant percentage movement both up and down looks considerable .

...and another one today